STAT+: Eli Lilly and AstraZeneca top a consultancy’s ranking of drug company R&D
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while AstraZeneca leads on invention.
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap — but when it comes to invention, AstraZeneca, with its wealth of experimental cancer and rare disease therapies, ranks above its peers.
The assessment, which is conducted by U.K.-based IDEA Pharma, ranks drug company laboratories on two different sets of criteria: innovation, which takes into account revenue from new products, new drug approvals, and major drug development events; and invention, which looks at the number of drugs a company has in development, its clinical trials, and its R&D investment, among other factors. IDEA is part of SAI MedPartners, a larger consultancy.
“Innovation, very simply for us, was about the creation of value from pipelines, including your ability to launch and to launch better than somebody else who does the same thing,” said Mike Rea, IDEA’s CEO. Invention, he said, is intended as a ranking of “what comes next.”
